Fifty 1 Labs, Inc. (FITY) Sparks AI Breakthrough in Drug Repurposing: Subsidiary Fifty1 AI Labs Announces Strategic Partnership with Intent to Acquire BioSpark AI Technologies
Unleashing Hidden Insights with AI-Powered Precision
This collaboration integrates BioSpark's proprietary AI and LLM platform with Fifty1 AI Labs' advanced predictive modeling to explore and organize extensive case-based medical literature. BioSpark's system automates the extraction, structuring, and indexing of real-world clinical data—covering patient journeys, treatment sequences, and outcomes—eliminating the inefficiencies of manual analysis. This empowers Fifty1 AI Labs to identify overlooked therapeutic patterns in longitudinal medical narratives, case series, and observational reports with unprecedented efficiency and scale.
"Combining BioSpark's sophisticated insight engine with our predictive AI platform unlocks a wealth of untapped clinical knowledge," said Paul Arora, CEO of Fifty1 AI Labs. "This partnership, with our intent to acquire BioSpark, accelerates our ability to identify promising drug repurposing candidates, delivering innovative treatments to patients faster and solidifying our leadership in AI-powered functional medicine."
A Synergistic Leap Toward Next-Generation Drug Repurposing
By merging BioSpark's expertise in converting unstructured clinical data into structured, queryable formats with Fifty1 AI Labs' proprietary Bayesian inference and polypharmacy modeling, this partnership pioneers an advanced approach to drug repurposing, grounded in real-world clinical experiences and enhanced by AI-driven analytics. Fifty1 AI Labs will process, prioritize, and evaluate BioSpark-generated insights to streamline the transition from literature discoveries to clinical trials, focusing on high-potential sectors like performance health, chronic disease prevention, and wellness enhancement.
This strategic alliance, with the intent to fully acquire BioSpark, strengthens Fifty1 AI Labs' visionary approach to dominating preventative healthcare through personalized, data-driven strategies and rapid candidate identification. It will fuel the development of repurposed formulations, incorporating proprietary transdermal and sublingual delivery systems optimized for superior patient outcomes. BioSpark's scalable literature mining capabilities will serve as a cornerstone in Fifty1's discovery and formulation processes.
A Shared Vision for Human-AI Collaboration
Bound by a shared commitment to enhancing human expertise with ethical, transparent AI tools, Fifty1 AI Labs and BioSpark AI Technologies aim to tap into the vast, often-overlooked potential within functional medicine that traditional clinical trials may miss. Through modern AI solutions, this partnership seeks to harness these opportunities securely, effectively, and at scale, while preserving researchers' intuitive judgment.
"BioSpark's platform transforms complex clinical data into actionable knowledge for experts," said a BioSpark AI spokesperson. "Partnering with Fifty1 AI Labs, with their intent to acquire our technology, amplifies this impact, driving progress in functional medicine and drug repurposing through our shared vision for human-AI collaboration."
About BioSpark AI Technologies Inc.
Founded in 2022 in Vancouver, Canada, BioSpark AI Technologies Inc. specializes in organizing and integrating real-world clinical data using proprietary AI and LLM technologies. Holding a U.S. patent (US 20250029734 A1) for its AI system that automates patient journey extraction and structuring from unstructured medical literature, BioSpark enables scalable, precise automation for clinical development, outcomes research, and medical advancements. Learn more at http://www.biospark.ai.
About Fifty1 AI Labs, LLC
Based in Seattle, Washington, Fifty1 AI Labs, LLC—a subsidiary of Fifty 1 Labs, Inc. (OTC: FITY)—is at the forefront of AI-driven functional medicine. Dedicated to transforming preventative healthcare and wellness, the company combines predictive AI with deep clinical insights to innovate in drug repurposing and formulation, addressing critical needs in performance health, chronic disease prevention, and personalized medicine.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's future financial and operating performance, business strategy, plans, objectives, expectations regarding future events or performance, and the potential acquisition of BioSpark AI Technologies Inc. These statements are based on current expectations, estimates, forecasts, and projections, and involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. The company undertakes no obligation to update or revise any forward-looking statements, except as required by law. For additional details, refer to the company's filings with the Securities and Exchange Commission.
Contact:
Investor Relations Fifty 1 Labs, Inc. Email: ir@fifty1labs.com Phone: (877) 505-5006 Website: www.fifty1AIlabs.com
Wire Service Contact: IBN Austin, Texas www.InvestorBrandNetwork.com 512.354.7000 Office Editor@InvestorBrandNetwork.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
With 65% institutional ownership, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a favorite amongst the big guns
Key Insights Given the large stake in the stock by institutions, Rigel Pharmaceuticals' stock price might be vulnerable to their trading decisions 51% of the business is held by the top 9 shareholders Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a company This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. To get a sense of who is truly in control of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), it is important to understand the ownership structure of the business. With 65% stake, institutions possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of weight, especially with individual investors. As a result, a sizeable amount of institutional money invested in a firm is generally viewed as a positive attribute. Let's take a closer look to see what the different types of shareholders can tell us about Rigel Pharmaceuticals. Check out our latest analysis for Rigel Pharmaceuticals What Does The Institutional Ownership Tell Us About Rigel Pharmaceuticals? Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index. We can see that Rigel Pharmaceuticals does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Rigel Pharmaceuticals' earnings history below. Of course, the future is what really matters. Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. It would appear that 15% of Rigel Pharmaceuticals shares are controlled by hedge funds. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. Our data shows that BlackRock, Inc. is the largest shareholder with 9.7% of shares outstanding. Armistice Capital LLC is the second largest shareholder owning 8.5% of common stock, and Morgan Stanley, Investment Banking and Brokerage Investments holds about 8.3% of the company stock. Furthermore, CEO Raul Rodriguez is the owner of 0.8% of the company's shares. We did some more digging and found that 9 of the top shareholders account for roughly 51% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat. While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future. Insider Ownership Of Rigel Pharmaceuticals While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. Shareholders would probably be interested to learn that insiders own shares in Rigel Pharmaceuticals, Inc.. As individuals, the insiders collectively own US$5.5m worth of the US$392m company. Some would say this shows alignment of interests between shareholders and the board. But it might be worth checking if those insiders have been selling. General Public Ownership With a 19% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Rigel Pharmaceuticals. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. Next Steps: It's always worth thinking about the different groups who own shares in a company. But to understand Rigel Pharmaceuticals better, we need to consider many other factors. For example, we've discovered 1 warning sign for Rigel Pharmaceuticals that you should be aware of before investing here. If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
STERIS (NYSE:STE) Will Pay A Larger Dividend Than Last Year At $0.63
STERIS plc's (NYSE:STE) periodic dividend will be increasing on the 26th of September to $0.63, with investors receiving 11% more than last year's $0.57. Despite this raise, the dividend yield of 1.0% is only a modest boost to shareholder returns. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. STERIS' Payment Could Potentially Have Solid Earnings Coverage It would be nice for the yield to be higher, but we should also check if higher levels of dividend payment would be sustainable. Before making this announcement, STERIS was easily earning enough to cover the dividend. This means that most of what the business earns is being used to help it grow. Looking forward, earnings per share is forecast to rise by 59.3% over the next year. If the dividend continues on this path, the payout ratio could be 26% by next year, which we think can be pretty sustainable going forward. See our latest analysis for STERIS STERIS Has A Solid Track Record The company has a sustained record of paying dividends with very little fluctuation. Since 2015, the dividend has gone from $0.92 total annually to $2.28. This implies that the company grew its distributions at a yearly rate of about 9.5% over that duration. Companies like this can be very valuable over the long term, if the decent rate of growth can be maintained. We Could See STERIS' Dividend Growing The company's investors will be pleased to have been receiving dividend income for some time. We are encouraged to see that STERIS has grown earnings per share at 5.2% per year over the past five years. Growth in EPS bodes well for the dividend, as does the low payout ratio that the company is currently reporting. We Really Like STERIS' Dividend Overall, a dividend increase is always good, and we think that STERIS is a strong income stock thanks to its track record and growing earnings. Earnings are easily covering distributions, and the company is generating plenty of cash. Taking this all into consideration, this looks like it could be a good dividend opportunity. Market movements attest to how highly valued a consistent dividend policy is compared to one which is more unpredictable. At the same time, there are other factors our readers should be conscious of before pouring capital into a stock. As an example, we've identified 1 warning sign for STERIS that you should be aware of before investing. Looking for more high-yielding dividend ideas? Try our collection of strong dividend payers. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
Here's How Long $1 Million in Retirement Savings Will Last You After Age 70
How long $1 million in retirement savings will last as a 70-year-old depends on a number of factors, including where you live, what type of lifestyle you lead, how healthy you are and how much insurance coverage you have. Here's a look at how these factors affect how long your savings will last, using Bureau of Labor Statistics data regarding average expenses in that age group. Check Out: Read Next: BLS Statistics The U.S. Bureau of Labor Statistics conducts an annual survey of the average annual expenditures of Americans across various age groups. The most recent data, for the year 2023, shows that Americans 65 and older — of which 70-year-olds are obviously a part — spent an average of $60,087 for the year. Using a straight mathematical average, this would suggest that for the average 70-year-old, $1 million would last approximately 16.64 years, or until they are nearly 87. Watch Out: How Health and Insurance Play a Role Generally speaking, healthcare costs increase after you retire. Even if you consider yourself relatively healthy, there's no telling how many injuries, illnesses or chronic conditions you may have to deal with as you get older. While genetics and personal lifestyle choices can prolong your life, there are no guarantees when it comes to health. Obviously, frequent trips to doctors and hospitals can quickly add to your expenses, shortening the duration of your $1 million. This is one of the reasons why good health insurance is essential in terms of the survival of your $1 million nest egg. If you have to pay out of pocket for your healthcare as you age, you could quickly increase that 'average' $60,087 annual spend to $100,000 or more, rapidly depleting your savings. Another factor to consider is that if you actually remain healthy and live a long life, you'll need to stretch that $1 million in retirement savings even further. A nest egg that only lasts for 17 years after average spending won't do you much good if you're going to live 30 years or more in retirement. In that scenario, you'll either need to boost your savings or learn how to live off less. Budgeting and Lifestyle Factors The way you live your life can have a huge effect on how long your money will last in retirement. Assuming an 'average' lifestyle, a pot of $1 million would last you about 17 years. But few retirees living in Manhattan, for example, could get by on $5,000 per month, even if they consider themselves frugal. In that scenario, $1 million may only last 10 years or less. But if you live a simple life in a rural community in Mississippi, for example, your money might last 30 years or more. The key to making your retirement savings last is to create a realistic budget. It's this simple — if you can live well beneath your means, then your $1 million will last longer. If you live a rockstar lifestyle, it will last less. The Importance of Investment Returns Very few people with $1 million simply keep it 'under a mattress,' or in an account that doesn't earn any interest. At the very least, most people with seven-figure account values keep that money in a low-risk, low-return investment like a high-yield savings account or a U.S. Treasury bill. Those with a bit more risk tolerance may keep some or even all of that amount potentially higher-yielding investments like intermediate-term bonds or dividend-paying stocks. Either way, it's highly likely that by taking on even a little bit of risk you can earn much more than 0% on your $1 million nest egg in retirement — and with higher returns, you can greatly extend the life of your nest egg. As shown above, it would take roughly 17 years for the average 70-year-old American to spend $1 million. But if you could earn even a 3% return on the $1 million, it could instead last for about 21 years. Boosting that return to 6% would nearly double the time that your money would last, to over 33 years. This simple example shows the immense power of investment returns when it comes to the longevity of your nest egg. More From GOBankingRates Mark Cuban Warns of 'Red Rural Recession' -- 4 States That Could Get Hit Hard 4 Housing Markets That Have Plummeted in Value Over the Past 5 Years 6 Hybrid Vehicles To Stay Away From in Retirement This article originally appeared on Here's How Long $1 Million in Retirement Savings Will Last You After Age 70 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
